NCT04086472: A reported trial by Merck Sharp & Dohme LLC
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04086472 |
|---|---|
| Title | A Phase 2a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Participants Inoculated With Experimental Respiratory Syncytial Virus |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 28, 2019 |
| Completion date | March 22, 2020 |
| Required reporting date | March 22, 2021, midnight |
| Actual reporting date | March 18, 2021 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |